A ROS-responsive synergistic delivery system for combined immunotherapy and chemotherapy

Immune checkpoint blockade (ICB) therapies that target programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway are currently used for the treatment of various cancer types. However, low response rates of ICB remain the major issue and limit their applications in clinic. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Doudou, Zhang, Wei, Xiang, Jiajia, Li, Dongdong, Chen, Yong, Yuan, Pengcheng, Shao, Shiqun, Zhou, Zhuxian, Shen, Youqing, Tang, Jianbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130108/
https://www.ncbi.nlm.nih.gov/pubmed/35647515
http://dx.doi.org/10.1016/j.mtbio.2022.100284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130108/
https://www.ncbi.nlm.nih.gov/pubmed/35647515
http://dx.doi.org/10.1016/j.mtbio.2022.100284

Ejemplares similares